Drug Discovery World

APRIL 22, 2024

Scientists have discovered how skin cancer cells shapeshift based on their environment – enabling them to spread through the body and cause a metastatic cancer. The discovery of two genes responsible for sensing the environment and adapting cell shape could offer potential new drug targets to stop cancer from metastasising. Cancer cells can change shape to move around the body, becoming drill-shaped to ‘poke’ through dense tissue like bone, or round and squishy to squeeze through soft tissues an

Drugs 52

Drugs Gene Scientist Research 52

Bio Pharma Dive

APRIL 22, 2024

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

Manufacturing 278

Manufacturing Medicine Drugs 278

Pharmaceutical Technology

APRIL 22, 2024

Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.

Containment 258

Containment Protein 258

Bio Pharma Dive

APRIL 22, 2024

A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of the complex cellular treatments.

Production 300

Production Manufacturing 300

Advertisement

Clinical Supply

Pharmaceutical Technology

APRIL 22, 2024

Discover how Avidity Biosciences' patented polynucleic acid molecule conjugate targets the DUX4 gene to combat FSHD. Learn more about this groundbreaking approach in gene therapy.

Gene Therapy 246

Gene Therapy RNA Gene 246

Bio Pharma Dive

APRIL 22, 2024

A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.

Drugs 283

Drugs Research 283

Bio Pharma Dive

APRIL 22, 2024

A new initiative backed by Takeda, Astellas and Sumitomo Mitsui Banking aims to combat a decade-long decline in drug R&D productivity in Japan.

Drugs 177

Drugs Research Production 177

Pharmaceutical Technology

APRIL 22, 2024

GS-6212 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS).

Clinical Development 245

Clinical Development Development 245

Bio Pharma Dive

APRIL 22, 2024

Treatment delays can seriously impact patients’ health outcomes. But by leveraging digital tools, pharma can help them find and access specialist care early in their journey.

152

152

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Non-Small Cell Lung Cancer.

Clinical Development 238

Clinical Development Development 238

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Bio Pharma Dive

APRIL 22, 2024

The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.

RNA 161

RNA Development Drugs Research 161

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Renal Cell Carcinoma.

Clinical Development 244

Clinical Development Development 244

pharmaphorum

APRIL 22, 2024

Pharmaceutical companies stand to gain significant benefits from technological innovation in the form of improved data analytics, streamlined healthcare processes, and enhanced patient outcomes. Explore the potential advantages for the pharma industry.

119

119

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Esophageal Cancer.

Clinical Development 241

Clinical Development Development 241

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

BioSpace

APRIL 22, 2024

The regulator on Monday slapped Abeona Therapeutics with a Complete Response Letter for its investigational cell therapy pz-cel due to chemistry, manufacturing and controls issues.

Regulation 115

Regulation Manufacturing 115

Pharmaceutical Technology

APRIL 22, 2024

AST-001 is under clinical development by Ascentawits Pharmaceuticals and currently in Phase II for Rectal Cancer.

Clinical Development 245

Clinical Development Development 245

BioSpace

APRIL 22, 2024

Bouncing back from a previous rejection, ImmunityBio on Monday secured the FDA’s green light for its IL-15 superagonist Anktiva for non-muscle invasive bladder cancer.

FDA Approval 109

FDA Approval 109

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase I for Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer).

Clinical Development 189

Clinical Development Development 189

Advertisement

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

Clinical Trials

pharmaphorum

APRIL 22, 2024

Discover the innovative use of artificial intelligence (AI) in drug discovery with a focus on GenAI and Large Language Models (LLMs) on Day Two of this informative event. Explore how technology is revolutionising the pharmaceutical industry.

Drugs 107

Drugs 107

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Epithelial Ovarian Cancer.

Clinical Development 189

Clinical Development Development 189

pharmaphorum

APRIL 22, 2024

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials. TGCT is a rare disease affecting the joints and tendons caused by overproduction of the protein CSF-1, which stimulates the proliferation of various cell types, inflammation, and destruction of the matrix of the joint.

Trials 105

Trials Protein Drugs 105

Pharmaceutical Technology

APRIL 22, 2024

Datopotamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Metastatic Ovarian Cancer.

Clinical Development 189

Clinical Development Development 189

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Clinical Supply

XTalks

APRIL 22, 2024

Stop Food Waste Day 2024 , set for April 24, marks a significant international day of action dedicated to combating the global food waste crisis. This initiative, launched by Compass Group in 2017, emphasizes the crucial role of corporations and the food industry in addressing this issue. With roughly one-third of all food produced globally lost or wasted, the food industry is pivoting towards sustainable practices aimed at curbing these losses.

Production 105

Production 105

Pharmaceutical Technology

APRIL 22, 2024

Develop a stable cell line for high-titer rAAV production with Ultragenyx's patented method involving HDAC inhibitors and AAV rep proteins. Explore the groundbreaking patent now!

Development 130

Development Protein Production 130

Fierce Pharma

APRIL 22, 2024

Sanofi will pay $100 million—or approximately $25,000 each—to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (rani | Sanofi will pay approximately $25,000 per person to roughly 4,000 claimants who filed lawsuits saying that the French company failed to warn users that its heartburn medicine Zantac (ranitidine) can cause cancer, Bloomberg reported.

Medicine 102

Medicine 102

Pharmaceutical Technology

APRIL 22, 2024

Wave Life Sciences Ltd patent reveals a groundbreaking method for synthesizing high-purity oligonucleotides with increased yields. Learn more about this innovative process now!

Life Science 130

Life Science 130

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

BioSpace

APRIL 22, 2024

Data from the Phase III LUNA 3 study on Tuesday showed that Sanofi’s BTK inhibitor rilzabrutinib significantly improved durable platelet response in patients with chronic immune thrombocytopenia.

98

98

Pharmaceutical Technology

APRIL 22, 2024

Radius Pharmaceuticals presented real-world evidence at the World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases on 12 April 2024, demonstrating that Tymlos therapy resulted in a lower incidence of hip and nonvertebral fractures compared to teriparatide therapy in women with osteoporosis aged 50 and older.

130

130

Fierce Pharma

APRIL 22, 2024

After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. | After a merger and an FDA rejection, celebrity businessman and biotech entrepreneur Patrick Soon-Shiong’s ImmunityBio has landed the company’s first U.S. approval in the cancer immunotherapy Anktiva.

FDA Approval 100

FDA Approval 100

Pharmaceutical Technology

APRIL 22, 2024

Discover the groundbreaking patent by Purdue Pharma for treating T-cell prolymphocytic leukemia with tinostamustine. Learn about the innovative kit and dosage guidelines for effective T-PLL treatment.

130

130

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Clinical Supply